Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

544 ARTÍCULOS , VIENDO DEL 481 AL 495

Dysregulated mTOR signaling in Alzheimer's disease: Linking pathogenic mechanisms to emerging therapeutic strategies

Zhang S, Wang T, Xue G, Zheng R, Ding N, Yang J, Zhang M.

J Alzheimers Dis. 2026 Jan;109(2):526-544. doi: 10.1177/13872877251400667. Epub 2025 Dec 8.

The dysregulation of innate immunity by Porphyromonas gingivalis in the etiology of Alzheimer's disease

Barron AE, Lin JS, Ryder MI, Bergman P.

J Intern Med. 2026 Mar;299(3):328-348. doi: 10.1111/joim.70060. Epub 2025 Dec 22.

Antimicrobial peptides inhibit Tau aggregation and modulates its pathology

Chinnathambi S, Rangappa N, Malik S.

Adv Protein Chem Struct Biol. 2026;149:375-394. doi: 10.1016/bs.apcsb.2025.09.002. Epub 2025 Oct 8.

Antimicrobial peptides act as a component of brain immunity against microbes in Alzheimer's disease

Chandrashekar M, Velmurugan G, Mishra A, Chinnathambi S.

Adv Protein Chem Struct Biol. 2026;149:395-418. doi: 10.1016/bs.apcsb.2025.10.016. Epub 2025 Nov 8.

Cytoskeletal proteins regulates Tau protein in Alzheimer's disease

Chinnathambi S, Adityan A.

Adv Protein Chem Struct Biol. 2026;150:1-28. doi: 10.1016/bs.apcsb.2025.10.029. Epub 2025 Nov 14.

The dynamics of podosomes, extracellular matrix-associated proteins regulate the cytoskeletal remodeling, mechanosensing, migration in Tau

Velmurugan G, Malik S, Mishra AK, Chinnathambi S.

Adv Protein Chem Struct Biol. 2026;150:221-243. doi: 10.1016/bs.apcsb.2025.10.021. Epub 2025 Nov 20.

Understanding the impact of cytoskeleton disruption on synaptic plasticity in Alzheimer's disease

Kc B, Priyadarshini P.

Adv Protein Chem Struct Biol. 2026;150:285-318. doi: 10.1016/bs.apcsb.2025.10.020. Epub 2025 Nov 13.

Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's disease

Chinnathambi S, Rangappa N, Chandrashekar M.

Adv Protein Chem Struct Biol. 2026;151:225-265. doi: 10.1016/bs.apcsb.2025.10.002. Epub 2025 Nov 5.

Clinical and functional evidence supporting the pathogenicity of the novel PSEN1 p.R358P variant in early-onset Alzheimer's disease

García-Chialva DE, Itzcovich T, Cifarelli D, Apecetche M, Chrem-Méndez P, Magrath-Guimet N, Vazquez S, Bérgamo Y, Allegri R, Marazita M, Sevlever GE, Isaja L, Surace EI, Romorini L.

J Alzheimers Dis. 2026 Jan;109(1):114-124. doi: 10.1177/13872877251392236. Epub 2025 Nov 6.

A unified 3D reconstruction of microscopy and MRI in a brain showing Alzheimer's disease-related neuropathology

Alkemade A, Bazin PL, Kirilina E, Pine K, Herrler A, Bleijs RLAW, Kros JM, Groenewegen L, Vermorgen SMM, Jonkman LE, Swaab DF, Balesar R, Weiskopf N, Forstmann BU.

Brain Pathol. 2026 Mar;36(2):e70039. doi: 10.1111/bpa.70039. Epub 2025 Sep 11.

Paratonia in dementia: diagnosis and management strategies

Joshi S, Chutia P, Tripathi SM.

Neurodegener Dis Manag. 2026 Apr;16(2):173-176. doi: 10.1080/17582024.2025.2591413. Epub 2025 Nov 18.

Challenging the boundaries: c9orf72 mutation presenting as Alzheimer's disease

Garrou F, De Marchi F, Corrado L, Sacchetti GM, D'alfonso S, Morbelli SD, Perani D, Mazzini L, Tondo G.

Amyotroph Lateral Scler Frontotemporal Degener. 2026 Feb;27(1-2):215-218. doi: 10.1080/21678421.2025.2541761. Epub 2025 Aug 6.

Comparison of treatment schedules on cognitive effects of rTMS in the 3xTg-AD model of Alzheimer's disease

Heath AM, Mojabi FS, Kraybill EP, Beard C, Venkataramanan V, Cuéllar V, Piekarski D, McNerney MW.

Exp Neurol. 2026 Feb;396:115551. doi: 10.1016/j.expneurol.2025.115551. Epub 2025 Nov 12.

Brain topology alteration in Alzheimer's disease brain networks: A multi-center study

Ma L, Wang P, Wang D, Yao H, Zhou B, Zhao Y, Liao Z, Chen Y, Zhang X, Han Y, Lu J, Zhao K, Zhang Y, Liu Y; Alzheimer’s Disease Neuroimaging Initiative, for the Multi-Center Alzheimer’s Disease Imaging (MCADI) Consortium.

Neuroimage Clin. 2026;49:103919. doi: 10.1016/j.nicl.2025.103919. Epub 2025 Nov 30.

Tolerability of rivastigmine transdermal patch in patients with Alzheimer's disease: a narrative review

García Ribas G, Ferrer-Picón E.

Expert Opin Drug Saf. 2026 Apr;25(4):643-655. doi: 10.1080/14740338.2025.2576520. Epub 2025 Oct 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias